Overview: Sepsis Panel
Introduction: The Sepsis Panel is a diagnostic tool designed to screen for sepsis using whole blood samples. In India, sepsis causes ~1-2 million deaths/year (high in rural/low-SES due to delayed care, infections), with biomarkers procalcitonin and CRP aiding early identification. High morbidity from under-testing in febrile patients, limited labs, delayed antibiotics leading to septic shock or mortality. Per critical care practices aligned with ICMR and Indian Society of Critical Care Medicine guidelines, the test employs flow cytometry for procalcitonin and CRP over 1-2 days with high accuracy, valuable for differentiating bacterial infection and guiding antibiotic stewardship. This diagnostic falls under infection screening and targets patients with suspected sepsis (fever, hypotension, organ dysfunction), addressing accurate detection to guide early goal-directed therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling rapid sepsis biomarker assessment and reducing mortality. Its whole blood-based approach ensures reliable inflammatory marker detection.
Other Names: Sepsis Pnl.
FDA Status: FDA approved, CLIA certified for microbiology/hematology, compliant with 2025 standards.
Historical Milestone: Procalcitonin/CRP standard in sepsis guidelines; in India, used in ICUs.
Purpose: The test assesses 2 parameters including procalcitonin to guide sepsis screening, detect bacterial infection, inform antibiotics.
Test Parameters: 1. Procalcitonin, 2. CRP.
Pretest Condition: No fasting required; patients should have suspected sepsis.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for flow).
Medical History: Patients should provide details on fever, organ dysfunction.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected sepsis including death, benefits of screening, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using flow cytometry by trained personnel to ensure sterile technique and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or non-bacterial sepsis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Elevated procalcitonin/CRP indicates bacterial sepsis, necessitating specialist input.
Specialist Consultation: Intensivists should be consulted for management.
Additional Supporting Tests: Blood culture, lactate for confirmation.
Test Limitations: Inflammatory markers nonspecific; comprehensive approach required.
References: Indian Journal of Critical Care Medicine 2024, Sepsis Studies India 2023.
